This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
To most Nephrologists, Nephronophthisis (NPH) is considered to be a rare autosomal recessive paediatric disease. However, this article by Snoek et al challenges that belief, by examining the prevalence of mutations that cause NPH, in adults with end stage renal disease (ESRD). Read our NephJC summary below and come along to our Twitter Journal Club discussion to find out whether you might consider a diagnosis of NPH, next time you see that patient carrying a label of ‘ESRD, cause unknown’.
